+1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Research ArticleOpen Access

Successful Treatment of Hypertrophic Pachymeningitis Complicated with Myelodysplastic Syndromes with 5-Azacytidine

Volume 10 - Issue 2

Chisato Ashida*, Yuji Nozaki, Daisuke Tomita, Toshihiko Shiga, Masanori Funauchi and Itaru Matsumura

  • Author Information Open or Close
    • Department of Hematology and Rheumatology, Kindai University School of Medicine, Japan
    • *Corresponding author: Chisato Ashida, Department of Hematology and Rheumatology, Kindai University School of Medicine, 377-2 Oonohigashi, Osaka-Sayama, Osaka, 589-0014 Japan

Received: October 08, 2018;   Published: October 24, 2018

DOI: 10.26717/BJSTR.2018.10.001932

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


It is known that the causative diseases of secondary hypertrophic pachymeningitis (HP) include infections, malignant tumors, autoimmune diseases. Although myelodysplastic syndromes (MDS) are often accompanied by certain autoimmune diseases, secondary HP with MDS is rare. We here describe the patient with HP complicated by MDS and have severe resistance to the steroid therapy and successfully treated with the combination of corticosteroids and 5-Azacytidine (5-Aza). Administration of 5-Aza might be a useful therapeutic option for patients with refractory autoimmune diseases complicated with MDS.

Keywords: Autoimmune Diseases; Hypertrophic Pachymeningitis; Myelodysplastic Syndrome; Azacytidine

Abbreviations: HP: Hypertrophic Pachymeningitis; MDS: Myelodysplastic Syndromes; 5-Aza:5-Azacytidine; CRP:C-Reactive Protein; PR3-ANCA:PR3-Anti-Neutrophil Cytoplasmic Antibody; MPO-ANCA: MPO-Anti-Neutrophil Cytoplasmic Antibody; CE-MRI: Contrast Enhanced Magnetic Resonance Imaging; PSL: Prednisolone; mPSL: methyl-Prednisolone; AZA: Azacytidine

Abstract| Introduction | Case Report| Discussion| Conflict of Interest| References|